Isotretinoin exposure during pregnancy: Assessment of spontaneous reports in France

Drug Safety

Volumn 33, Issue 8, 2010, Pages 659-665

  Autret Leca, Elisabeth ^a,b   Kreft Jais, Carmen ^c   Elefant, Elisabeth ^d   Cissoko, Hawar ^a   Darrouzain, Franois ^a   Grimaldi Bensouda, Lamiae ^a,b   Attia, Sarah ^c   Jonville Bra, Annie Pierre ^a  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c division surveillance   (France)

^d Centre de Rfrence sur les Agents Tratognes   (France)

Author keywords

adverse reactions; Congenital abnormalities; drug induced; Isotretinoin; Pregnancy; Prescribing; Risk management; Teratogenesis

Indexed keywords

CONTRACNE; CURACNE; GENERIC DRUG; ISOTRETINOIN; PROCUTA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CONCEPTION; CONTRACEPTION; DERMATOLOGY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; EMBRYOPATHY; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PREGNANCY OUTCOME; PREGNANCY TEST; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; RISK; SELF MEDICATION; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; CONTRACEPTION; FEMALE; FRANCE; HEALTH PLANNING GUIDELINES; HUMANS; INFANT, NEWBORN; ISOTRETINOIN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; YOUNG ADULT;

EID: 77954699460     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11536250-000000000-00000     Document Type: Article

References (21)

1. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid em-bryopathy. N Engl J Med 1985; 313: 837-41
2. Robertson R, MacLeod PM. Acutane-induced teratogenesis. CMAJ 1985; 133: 1147-8
3. Autret E, Radal M, Jonville-Bera AP, et al. Isotretone (Roaccutane®) chez la femme en age de procreer: in-suffisance de suivi des recommandations de prescription. Ann Dermatol Venereol 1997; 124: 518-22
4. Autret-Leca E, Jonville-Bera AP, Szafir D, et al. Roaccutane® chez la femme en age de procreer: etude de l'impact du renforcement des recommandations de prescription. Ann Dermatol Venereol 2000; 127: 808-13
5. Bensouda-Grimaldi L, Jonville-Bera AP, Mouret E, et al. Isotretino?ne: suivi de l'application des recommandations des prescripteurs chez les femmes en age de procreer. Ann Dermatol Venereol 2005; 132: 415-23
6. Dictionnaire Vidal®. 81st ed. Paris: Editions Vidal, 2005
7. Cheetham TC, Wagner RA, Chiu G, et al. A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study. J Am Acad Dermatol 2006; 55: 442-8
8. Strauss JS, Leyden JJ, Lucky AW, et al. Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol 2001; 45: 196-207
9. Mitchell AA, Van Bennekom CM. Accutane and pregnancy. J Am Acad Dermatol 2003; 49: 1201-2
10. Mitchell AA, Van Bennekom CM, Louik C. A pregnancyprevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333: 101-6
11. Mitchell AA, Van Bennekom CM, Louik C. An assessment of the Acutane (isotretinoine) pregnancy program. FDA Dermatologic Drugs Advisory Committee Meeting; 2000 Sep 18; Gaithersburg (MD) [online]. Available from URL: www.fda.gov/ohrms/dockets/ac/00/backgrd/3639b1c-03.pdf [Accessed 2010 May 17]
12. Berard A, Azoulay L, Koren G, et al. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007; 63: 196-205
13. Koren G, Avner M, Shear N. Generic isotretinoin: a new risk for unborn children. CMAJ 2004; 170: 1567-8
14. Mendelsohn AB, Governale L, Trontell A, et al. Changes in isotretinoin prescribing before and after implementation of the System to Manage Accutane Related Teratogenicity™ (SMART™) risk management program. Pharmacoepide-miol Drug Saf 2005; 14: 615-8
15. Boucher N, Beaulac-Baillargeon L. Pregnancy prevention among women taking isotretinoin: failure to comply with the recommendations. Can Fam Physician 2006; 52: 338-9
16. Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies. Arch Dermatol 2005; 141: 563-9
17. Robertson J, Polifka JE, Avner M, et al. A survey of pregnant women using isotretinoin. Birth Defects Res A Clin Mol Teratol 2005; 73: 881-7
18. Garcia-Bournissen F, Tsur L, Goldstein LH, et al. Fetal exposure to isotretinoin: an international problem. Reprod Toxicol 2008; 25: 124-8
19. Honein MA, Lindstrom JA, Kweder SL. Can we ensure the safe use of known human teratogens? The iPLEDGE™ test case. Drug Saf 2007; 30: 5-15
20. De Santis M, Straface G, Cavaliere AF, et al. The need for restricted prescription of retinoic acid derivative isotretinoin to prevent retinoid teratogenicity. Prev Med 2007; 45: 243-4
21. Kanelleas AI, Thornton S, Berth-Jones J. Suggestions for effective contraception in isotretinoin therapy. Br J Clin Pharmacol 2008; 67: 137-8